ProCE Banner Activity

As the Treatment of HER2-Negative Early Breast Cancer Evolves, So Does Our Corresponding Treatment Decision Support Tool

Clinical Thought

Read this expert commentary for an overview of our updated treatment decision support tool for HER2-negative early breast cancer, which provides current treatment recommendations from 5 experts.

Released: October 11, 2023

Share

Faculty

Laura M. Spring

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC in partnership with Smart Patients.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Merck Sharp & Dohme LLC.

AstraZeneca

Merck Sharp & Dohme, LLC

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Laura M. Spring, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Pharma, Lilly, G1 Therapeutics, Novartis, Puma; researcher (paid to institution): Genentech, Gilead, Lilly, Merck.